Introducing the
PangomerTM Chemistry Platform

A diverse class of therapeutic agents uniquely suited to target toxic intrinsically disordered proteins (IDPs) involved in the propagation of multiple diseases such as Type 2 Diabetes, neurodegeneration and cancers.

How It Works

IDPs are unstructured proteins, lacking the stable binding pockets needed for small molecule therapeutics, making them traditionally undruggable targets. Examples are: Islet amyloid polypeptide (IAPP), in the case of Type 2 Diabetes; alpha-synuclein, in the case of Parkinson’s Disease; and Myc, in the case of several tumors. During disease progression, IDPs miss-assemble and become toxic to cells.

Pangolin Therapeutics uses a combination of molecular modeling, biophysics, synthetic organic chemistry and other tools of drug discovery to produce Pangomers selectively designed to interfere with a specific toxic IDP and halt disease progression.

pangomer analogue binding
pangomer animation

Pangomers are Amazing Molecules

  • Features of peptide mimetics and small synthetic organics
  • Chemically tunable folding dynamics
  • Engage targets selectively, remodeling or dissociating them
  • Water Soluble
  • Membrane Penetrating
  • Stable
  • Safe

Pangolin Therapeutics’ Market Potential

IDPs comprise over one-third of the human proteome. Pangolin has the potential to build a rich pipeline of products in high medical need areas.

While today the focus is on Type 2 Diabetes, where there is an ever growing market and need for agents with new mechanisms of action, programs in neurodegeneration are underway.

Pangolin is about:

  • First-in-class drugs with the potential for disease modification or cure
  • Multiple assets ripe for collaboration and licensing
in NIH, state and private funding has been invested in the Pangomer Platform.
Contact us today to learn about investment opportunities.


in NIH, state and private funding has been invested in the Pangomer Platform.

Contact us today to learn about investment opportunities.
white Pangolin icon

Meet the Leadership

Pangolin Therapeutics is led by an experienced team that understands the business of science.

Enrique Alvarez Sotomayor

Enrique Alvarez Sotomayor, DMV, MA

Co-Founder, Senior VP Research and Development

  • 25-year Biotech & Pharma Pre-Clinical Expert
Susan Froshauer

Susan Froshauer, PhD

Chief Executive Officer

  • 30-year Biotech & Pharma Drug Discovery Scientist & Business Executive
Andrew Miranker

Andrew Miranker, PhD

Co-Founder, Scientific Advisory Board Chair

  • 25-year Computational Design, Biophysics & Biochemistry Leader
  • Professor, Molecular Biophysics & Biochemistry, Yale University

Pangolin Therapeutics is supported by an accomplished Scientific Advisory Board led by Dr. Miranker:

Peter Farina, PhD

  • Expertise: Organic chemistry, pharmaceutical R&D; 28 years of experience
  • Senior Vice President of Development, Boehringer Ingelheim NA

Carolyn Fredericks, MD

  • Expertise: Imaging, neurodegenerative diseases
  • Assistant Professor, Department Neurology, clinician, Yale School of Medicine

Andrew Hamilton, PhD, FRS

  • Expertise: Protein mimetic chemistry
  • Professor of Chemistry and President, New York University

Richard Kibbey, MD/PhD

  • Expertise: Islet biology, Type 2 Diabetes, clinician
  • Associate Professor of Internal Medicine, Endocrinology & Cellular & Molecular Physiology, Yale University

Liz Rhoades, PhD

  • Expertise: Biophysical chemistry of disordered proteins; 16+ years in Parkinson’s and TBI
  • Professor of Chemistry, University of Pennsylvania